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Abstract: A differential game is formulated in order to model the interaction between the
immune system and the HIV virus. One player is represented by the immune system of a
patient subject to a therapeutic treatment and the other player is the HIV virus. The aim of
our study is to determine the optimal therapy that allows to prevent viral replication inside the
body, so as to reduce the damage caused to the immune system, and allow greater survival
and quality of life. We propose a model that considers all the most common classes of
antiretroviral drugs taking into account different immune cells dynamics. We validate the
model with numerical simulations, and determine optimal structured treatment interruption
(STI) schedules for medications.
Keywords: mathematical modeling; human Immunodeficiency virus (HIV); acquired
immunodeficiency syndrome (AIDS); differential games
PACS classifications: 49N90; 97M60
1. Introduction
The genetic code of the HIV virus consists of a ribonucleic acid, the RNA. HIV belongs to the
retroviruses family, characterized by the presence of an enzyme, DNA-polymerase RNA-independent,
capable of transcribing the genetic code RNA into DNA. This ability allows the virus to integrate its
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genome into the one of the cells it infects, so that the integrated virus would not be defeated nor by the
immune response nor by drugs.
HIV has a marked tendency to mutate: mutations are errors that individual viral particles make in
replicative cycles. Each error leads to the appearance of a virus, which is more or less analogous to
the original one. Mutations are mostly “disadvantageous” for the viral species, as mutated viruses tend
to disappear. Nevertheless some mutations are “beneficial” and allow mutated viruses to acquire drug
resistance and immune response. One of the most effective mechanisms used by HIV to evade the
immune response and treatment is, in fact, its aptitude to change.
The main HIV target cells are T lymphocytes of type CD4, fundamental in the adaptive response
against a variety of pathogens and oncogenes.
The overall function of the immune system is to prevent or limit infections. An immune response
is generally divided into innate and adaptive immunity. Innate immunity occurs immediately, when
circulating innate cells recognize a problem. Adaptive immunity occurs later, as it relies on the
coordination and expansion of specific adaptive immune cells.
In particular, CD4+ lymphocytes are very important cells in the immune system, in fact they recognize
the various uninvited guests organism (viruses, bacteria, protozoa, fungi, worms and cancer cells)
through biochemical messages, and they activate the areas of the immune system most suitable to counter
their presence. A large number of CD4+ paralyzes the immune system, exposing the body to any risk of
infection and cancer [1].
Actually, HIV can be suppressed by a combination of antiretroviral therapy (ART) consisting of
three or more antiretroviral (ARV) drugs. In principle, ART cannot eradicate HIV infection from the
“sanctuaries” (mainly lymph-nodes and lymphatic system); it controls viral replication within a body
reducing viral burden, thus in turn it allows a functional improvement of an individual’s immune system
that basically regains the capacity to fight off infections [2]. It has been proved that people with HIV,
subject to ART therapy, can have a healthy and productive life, in fact after the advent of the ART therapy
the mortality curve of HIV-infected patients started to decline.
On the other hand, the lack of a definitive eradication of viral reservoirs determines two important
consequences: the anti-HIV treatment should be life-long; the longer the treatment, the more likely the
development of drug-resistance. On this basis, an intense research activity has been developed in last
decades, usefully enlarging the anti-HIV molecules repertoire. Actually there are more than 20 approved
antiretroviral drugs, divided into 6 different pharmacological classes. Anti-retroviral drugs are broadly
classified through the phase of the retrovirus life-cycle that they inhibit, as follows
• Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI);
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI);
• Protease inhibitors (PI);
• Fusion Inhibitors (FI);
• Coreceptor Antagonists (CA);
• Integrase Inhibitors (II).
Typical combinations involve the conjunctive use of either two NRTIs and one NNRTI, or one PI
(with or without Ritonavir) in combination with two NRTIs.
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HAART (Highly active antiretroviral therapy) is an abbreviation for all protocols involving
combinations of drugs, which are active against different molecular targets in the life cycle of HIV.
These medications are administered in the form of the high concentration cocktails. This approach was
born in 1995–1996 with the introduction of the second class of antiretroviral drugs: Protease inhibitor
(PI), administered in combination with drugs of the first generation, or Reverse Transcriptase Inhibitors
(NRTI and NNRTI: see zidovudine or AZT azidothymidine).
Among the benefits of treatment there is a decreased risk of progression to AIDS and a decreased risk
of death. The adverse effects and the complexity of treatment regimens (due to the high number of pills
and to dosing frequency) may reduce patient’s compliance [3].
A correct administration of antiretroviral drugs should be daily scheduled and uninterrupted; it
requires care and precision, even in relation to meals and to subministration of other drugs. The omission
of a few doses leads to a reduction of drug concentration in blood, therefore the residual level could
become lower than the one necessary to inhibit the virus. Not only does this allow the resumption of
viral replication, but it also facilitates the inexorable emergence of resistant virus. Resistant mutants tend
to persist, making the drug ineffective, even if the intake of drugs is carried out according to the rhythms
and the correct doses. A scarce adherence to the prescriptions and its consequent emergence of resistant
mutants may cause failure of the treatment.
The therapy must prevent viral replication in the body, rather than the complete eradication of the
infection, that remains chronic, so as to reduce the damage caused to the immune system and to allow
greater survival and quality of life.
The study of HIV biological evolution and of its relationship with the immune system is used to
determine a therapy policy that can defeat the viruses. Despite it seems counterintuitive, the aim is to
determine a proper dosage of drugs, which defends against viruses only moderately and which may
benefit both the host and the virus, i.e., without creating strong environmental pressures. A stable
long-term coexistence can be reached, hopefully avoiding drug-resistance development.
Mathematical modeling of HIV infection has proven to be instrumental for the modern understanding
basis of the AIDS pathogenesis [4]. There exist several attempts to formalize the evolution of HIV
and the use of drugs to limit its diffusion. Most of the related literature is linked to the study of the
HIV dynamics in the body and only few of them apply the Optimal control theory considering also the
possibility to control the drugs action. An exhaustive survey that collects all these works and classifies
them according to the most relevant criteria con be found in [5].
In this work we present an application of the differential Game Theory to a medical-therapeutic
context for the HIV treatment A first attempt has been performed by Wu and Zhang in [6]. Here we
present a differential game which considers the classes of antiretroviral drugs currently most used and
different immune cells dynamics, with the aim of representing as much as possible the real setting of this
problem. We consider two players: The HIV virus and the immune system, supported by antiretroviral
therapy. We look for an optimal therapeutic treatment in terms of a Nash Equilibrium, with the aim
of finding a proper dosage of drugs which defends against viruses, such that a stable long-term life
expectation may be obtained.
This paper is structured as follows. In Section 2 we introduce the involved variables and parameters
and we formalize the problem in terms of a differential game. In Section 3 we characterizes the Open
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Loop Nash Equilibrium. In Section 4 we present some numerical simulations to show two different
situations that may occur and how the algorithm performs. Section 5. concludes with some comments.
All analytical computations are reported in Appendix A within the Theorems’ proofs. In Appendix B
are listed the parameter values used in the numerical simulations.
2. The Model
We present a generalized model within the Game Theory approach, in order to determine the optimal
antiretroviral treatment against the HIV infection. We take into accounts 4 types of cells: HIV viruses,
CD4+ T Helper cells (adaptive immunity), macrophage and monocytes cells (innate immunity) and
immune precursor/effector Cytotoxic T lymphocyte cells.
After the primary HIV infection has established, an acute HIV syndrome appears with a wide
dissemination of viruses and with seeding of lymphoid organs. This phase can last between three and
nine weeks. From the ninth week the clinical latency phase may start, here the AIDS symptoms are not
macroscopically manifested, nevertheless the number of T lymphocytes begins to decrease and the viral
load increases. This stage can persist many years. Finally, at a last stage, there is the occurrence of the
AIDS symptoms and of other opportunistic infections. In addition, this stage can last for years and ends
with the death of the host [7]. As there exist so many strains of viruses, in order to take into account all
of them, without making the model intractable, we distinguish the HIV viruses between “sensitive”, (Vs)
and “resistant” (Vr) to the therapy.
In the model we adopt the idea of Herod et al. [8] and Nowak [9], assuming that the immune
response (Th) to a viral infection creates some subpopulations of lymphocytes (Ts ) that are specific
only for sensitive viruses, some others (Tr) that are specific only for resistant viruses, and finally the
subpopulation Tg that is effective against both sensitive and resistant viruses. Furthermore, the mutation
of the initial viral infection may cause the death of the entire population of lymphocytes.
Given the fact that HIV actually cannot be eradicated, our aim is to formulate a differential game
between HIV and the Immune System in which the existence of an equilibrium would lead to an optimal
drug therapy, which enables a stable long-term coexistence between virus and host, in other terms, a
longer life expectancy.
In the following tables we present, in alphabetical order for the symbols, the variables and the
parameters of the model. In particular: Table 1 lists the state functions; Table 2 lists the control functions
and finally Tables 3 and 4 list the parameters.
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Table 1. State functions (Unit of measure: cells/mm3).
Symbol Description
Ip Immune Precursor Cytotoxic T lymphocytes
Ie Immune Effector Cytotoxic T lymphocytes
Mh Uninfected macrophages
Mh,j Macrophage infected by viruses j
Th Uninfected CD4+ T Helper cells
Ts Uninfected CD4+ T Helper cells strain specific for Vs
Tr Uninfected CD4+ T Helper cells strain specific for Vr
Tg Uninfected CD4+ T Helper cells unspecific for Vs and Vr
T li,j Latently infected CD4+ Ti cells infected by virus j
T ai,j Actively infected CD4+ Ti cells infected by virus j
Vs HIV drugs sensitive viruses
Vr HIV drugs resistant viruses
Table 2. Control functions (bounded in [0, 1]).
Symbol Description
uco Dosage of coreceptor antagonists
ufi Dosage of fusion inhibitors
uib Immune boosting
uii Dosage of integrase inhibitors
upi Dosage of protease inhibitors
urt Dosage of reverse transcriptase inhibitors
uvr,r Mutation rate from resistant virus (Vr) to other resistant virus (Vr)
uvr,s Mutation rate from resistant virus (Vr) to sensitive virus (Vs)
uvs,r Mutation rate from sensitive virus (Vs) to resistant virus (Vr)
uvs,s Mutation rate from sensitive virus (Vs) to other sensitive virus (Vs)
Table 3. Parameters (Unit of measure: 1/day).
Symbol Description
c Cytotoxic T lymphocyte (CTL) activation rate
ij Death rate of cells infected by viruses Vj due to immune response
k Rate at which T cells convert to specific immune reaction cells (Ts or Tr)
k′ Rate at which T cells convert to unspecific immune reaction cells
k2 Rate at which latently infected cells convert to actively infected cells
µi Natural death rate of type i cells
pis Growth rate of sensitive viruses (Vs)
pir Growth rate of resistant viruses (Vr)
q Growth rate of Ie due to infected cells and Ip
r Growth rate for CD4+ T cell population
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Table 4. Parameters.
Symbol Description U.m./Value
Ai Weight on the benefit i and cost of therapy i ∈ [0,+∞]
Bi,j Weight of viral mutation from strain i to strain j ∈ [0,+∞]
b2 Half saturation constant mm3
g Input rate of external viral source cells
mm3×day
Ie0 Initial value of I
e cells cells
mm3
Ip0 Initial value of I
p cells cells
mm3
k1,j Rate at which viruses type j infect T cells mm
3
virions×day
kM1,j Rate at which viruses type j infect M cells
mm3
virions×day
k3 Rate at which infected macrophages infect T cells mm
3
cells×day
M0h Initial value of Mh cells
cells
mm3
Ma,0h,j Initial value of actively Mh cells infected by viruses Vj
cells
mm3
θi Scaling parameter for type i cells
p′j Specific immune response rate against viruses Vj
cells
mm3×day
Qi,j Percentage of i cells that recognize the virus j ∈ [0, 1]
ρj Average number of virions j infecting a cell virionscell
s1,j Source/production of type j cells cellsmm3×day
s′j Unspecific immune response rate against viruses Vj
cells
mm3×day
T 0i Initial value of Ti cells
cells
mm3
T l,0i,j Initial value of latently Ti cells infected by viruses Vj
cells
mm3
T a,0i,j Initial value of actively Ti cells infected by viruses Vj
cells
mm3
Tmax Maximum CD4+ T Helper cell population level cellsmm3
V 0j Initial value of viruses Vj
cells
mm3
Let us collect all the state variables in the following array:
x(t) =
(
Th(t), Ts(t), Tr(t), Tg(t),Mh(t), I
p(t), Ie(t), T lh,s(t), T
a
h,s(t), T
l
h,r(t),
T ah,r(t), T
l
s,s(t), T
a
s,s(t), T
l
s,r(t), T
a
s,r(t), T
l
r,s(t), T
a
r,s(t), T
l
r,r(t), T
a
r,r(t),
T lg,s(t), T
a
g,s(t), T
l
g,r(t), T
a
g,r(t),M
a
h,s(t),M
a
h,r(t), Vs(t), Vr(t)
)
.
The last four controls are related to the HIV player, nevertheless, in line with most notation of the
cited literature, we can limit to the two controls uvs,s and u
v
r,r only, observing that u
v
s,s = 1 − uvs,r and
uvr,r = 1− uvr,s.
Let’s collect the immune system-therapy controls in the array:
u1(t) =
(
uco(t), ufi(t), uib(t), uii(t), upi(t), urt(t)
)
and the viruses controls in the array:
u2(t) =
(
uvs,s(t), u
v
r,r(t)
)
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In Table 3 we show the parameters with the same unit of measure (1/day), while all the other
parameters are in Table 4.
HAART therapy can prolong the patient’s life, however, it has many side effects, so that a long-term
administration may become difficult and it is necessary to determine the minimal dose of drugs that
prevents the viral replication.
The immune system has to maximize the number of uninfected macrophages, uninfected T-cells, and
immuno precursors/effectors, minimizing, at the same time, the side effects of drugs. Such an object is
represented by the following payoff:
JTher
(
u1(t)
)
=
∫ tf
t0
[
Mh(t) + I
p(t) + Ie(t) +
∑
∀i∈Γ
Ti(t)− 1
2
∑
∀k∈Ω
Aku
2
k(t)
]
dt (1)
where Γ = {h, s, r, g} and Ω ∈ {co, fi, ib, ii, pi, rt}.
On the other hand, HIV tends to maximize the number of sensitive and resistant viruses, the number
of latently and actively infected T-cells, minimizing, at the same time, the mutation costs. Its payoff
fuction is:
JHIV
(
u2(t)
)
=
∫ tf
t0
[
Vs(t) + Vr(t) +
∑
∀i∈Γ
∀j∈Θ
(
T li,j(t) + T
a
i,j(t)
)
− 1
2
(
Bs,r
(
1− uvs,s(t)
)2
+Br,s
(
1− uvr,r(t)
)2)]
dt (2)
where Γ = {h, s, r, g} and Θ = {s, r}. Observe that drug toxicity costs and HIV mutation costs are
assumed quadratic in the controls to represent their increasing increments of scale.
The T-cells undergo to different evolutions depending on whether they have been infected or not by
the virus. In what follows we distinguish between uninfected and infected cells. In particular, we expose
the dynamics of the following five classes of cells:
1. Uninfected CD4+ T-helper cells;
2. Uninfected macrophages and CD8+ CTL precursors and effectors;
3. Latently and actively infected CD4+ T cells by sensitive and resistant viruses;
4. Infected macrophages by sensitive and resistant viruses;
5. Sensitive and resistant viruses;
Writing first the terms which contribute positively to their growth, and after the negative terms.
We also stress the features that characterize each group of cells.
The evolution of every type of cell is subject to a natural death rate that can be represented in its
dynamics by a (negative) decaying term. Namely, let xi ∈ x be a particular type of cell, such a decaying
term is −µxixi and appears at the end of each considered dynamics.
In the evolution of the uninfected CD4+ T-Helper cells we consider features taken from different
models by Kirschner et al. [10], Caetano et al. [11] and Joshi [12]. The dynamics are the following
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T˙h(t) =
s1,ThθTh
θTh +
(
Vs(t) + Vr(t)
)+ rTh(t) (1− ∑Ti(t) +∑T li,j(t) +∑T ai,j(t)
Tmax
)
+ uib(t)Th(t)
− k1,s
(
1− ufi(t)
)(
1− uco(t)
)(
1−QTh,Vs
)
Vs(t)Th(t)− k1,r
(
1−QTh,Vr
)
Vr(t)Th(t)
− kVs(t)Th(t)− kVr(t)Th(t)− k′
(
Vs(t) + Vr(t)
)
Th(t)
− k3
(
Mah,s(t) +M
a
h,r(t)
)
Th(t)− µThTh(t) (3)
T˙s(t) = kVs(t)Th(t) + uib(t)Ts(t)
− k1,s
(
1− ufi(t)
)(
1− uco(t)
)(
1−QTs,Vs
)
Vs(t)Ts(t)− k1,r
(
1−QTs,Vr
)
Vr(t)Ts(t)
− k3
(
Mah,s(t) +M
a
h,r(t)
)
Ts(t)− µTsTs(t) (4)
T˙r(t) = kVr(t)Th(t) + uib(t)Tr(t)
− k1,s
(
1− ufi(t)
)(
1− uco(t)
)(
1−QTr,Vs
)
Vs(t)Tr(t)− k1,r
(
1−QTr,Vr
)
Vr(t)Tr(t)
− k3
(
Mah,s(t) +M
a
h,r(t)
)
Tr(t)− µTrTr(t) (5)
T˙g(t) = k
′(Vs + Vr(t))Th(t) + uib(t)Tg(t)
− k1,s
(
1− ufi(t)
)(
1− uco(t)
)(
1−QTg ,Vs
)
Vs(t)Tg(t)− k1,r
(
1−QTg ,Vr
)
Vr(t)Tg(t)
− k3
(
Mah,s(t) +M
a
h,r(t)
)
Tg(t)− µTgTg(t) (6)
One common characteristic among the above cells is constituted by the presence of the immune
busting effect that causes an increase of the immune barriers, see [12]. It is proportional to the number
of particular uninfected CD4+ T-Helper cells and it depends on the control uib. Note the positive term
uib(t)Ti, i ∈ Γ = {h, s, r, g} that appears at the end of the first line in the dynamics of each type of
cell Ti.
Moreover, some cells are infected by sensitive viruses: Their number is proportional to the number of
sensitive viruses (Vs) and to the dimension of the community of cells itself. Coefficient k1,s represents
the infection rate, the factors
(
1− ufi(t)
)
and
(
1− uco(t)
)
describe the actions of fusion inhibitors and
coreceptor antagonists against the infection of the cells. These drugs interfere with binding, fusion and
entry of HIV to the host cell. Finally (1 − QTi,Vs
)
is the portion of generic CD4+ T Helper cells that
does not recognize and does not obstruct sensitive viruses. Similarly, cells are infected also by resistant
viruses, and their number is proportional to the number of resistant viruses (Vr) and to the dimension
of the community of cells itself. What makes the difference is that fusion inhibitors and coreceptor
antagonists can not counteract Ti cells infection by resistant viruses (Vr), therefore the drugs action is
null. The factor (1 − QTi,Vr
)
is the portion of generic CD4+ T Helper cells that does not recognize and
does not obstruct resistant viruses. These effects are represented by the second lines of the dynamics.
Observe that the negative terms−kVs(t)Th(t)−kVr(t)Th(t)−k′
(
Vs(t)+Vr(t)
)
Th(t) which appear in
the third line of Equation (3) represent the number of Th cells converted to Ts, Tr or Tg cells respectively.
Each one of such terms obviously appears with a positive sign in Equations (4)–(6) for uninfected Ts, Tr
and Tg cells.
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The term−k3
(
Mah,s(t)+M
a
h,r(t)
)
gives the portion of Ti cells contaminated by infected macrophages,
and the sensitivity/resistant differentiation in it constitutes a novelty of our model.
Once explained the common features of the CD4+ T-Helper cells, let’s explicate the terms which
characterise the dynamics of the naive T lymphocytes (Th) in Equation (3).
The term:
s1,ThθTh
θTh +
(
Vs(t) + Vr(t)
)
gives the proliferation of uninfected CD4+ Th cells. It includes both an external (not plasma) contribution
of cells from sources, such as the thymus and lymph nodes, and an internal (plasma) contribution from
CD4+ Th cells differentiation.
The term:
rTh(t)
(
1−
∑
Ti(t) +
∑
T li,j(t) +
∑
T ai,j(t)
Tmax
)
represents the production of Th-cells due to cloning in the presence of an antigen, taking into account
the maximum number of lymphocytes, Tmax.
The dynamics for the uninfected macrophages, CD8+ CTL precursors and effectors are
the following:
M˙h(t) = s1,Mh − kM1,s
(
1− urt(t)
)(
1− upi(t)
)
Vs(t)Mh(t)− kM1,rVr(t)Mh(t)− µMhMh(t) (7)
I˙p(t) = cIp(t)
∑
Ti(t)
∑
T ai,j(t)− cqIp(t)
∑
T ai,j(t)− µIpIp(t) (8)
I˙e(t) = cqIp(t)
∑
T ai,j(t)− µIeIe(t) (9)
According with [10], macrophages dynamics Equation (7) consider a constant proliferation source
(s1,Mh) and sensitive and resistant infections elements −kM1,s
(
1 − urt(t)
)(
1 − upi(t)
)
Vs(t)Mh(t) −
kM1,rVr(t)Mh(t). Here reverse transcriptase inhibitors (RTI) and protease inhibitors (PI) counteract the
action of sensitive viruses. In particular the first ones inhibit reverse transcription, and the second
ones block the viral protease enzyme necessary to produce mature virions upon budding from the host
membrane. Each one of such terms obviously appears with a positive sign in Equations (26) and (27).
About immune precursors/effectors (Ip, Ie) dynamics Equations (8) and (9) we extend the model
presented by Wodarz and Nowak in [13] by differentiating infected T-cells with actively infected
Th, Ts, Tr and Tg cells (
∑
T ai,j).
If a Th cells is infected it becomes either latently or actively infected. The latently infected cells (T lh,j
with j ∈ {s, r}) can be activated and become actively infected (T ah,j with j ∈ {s, r}) their activation
rate is denoted by k2. The actively infected cells are short living and will normally be killed upon
activation with a high death rate µTah,j with j ∈ {s, r}. Latently and actively infected T-cells dynamics
are the following:
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T˙ lh,s(t) = k1,s
(
1− ufi(t)
)(
1− uco(t)
)(
1−QTh,Vs
)
Vs(t)Th(t) + k3M
a
h,s(t)Th(t)
− k2
(
1− urt(t)
)(
1− uii(t)
)
T lh,s(t)− µT lh,sT
l
h,s(t) (10)
T˙ ah,s(t) = k2
(
1− urt(t)
)(
1− uii(t)
)
T lh,s(t)− isIe(t)T ah,s(t)− µTah,sT ah,s(t) (11)
T˙ lh,r(t) = k1,r
(
1−QTh,Vr
)
Vr(t)Th(t) + k3M
a
h,r(t)Th(t)− k2T lh,r(t)− µT lh,rT
l
h,r(t) (12)
T˙ ah,r(t) = k2T
l
h,r(t)− irIe(t)T ah,r(t)− µTah,rT ah,r(t) (13)
The positive terms +k1,s
(
1 − ufi(t)
)(
1 − uco(t)
)(
1 − QTh,Vs
)
Vs(t)Th(t) + k3M
a
h,s(t)Th(t) in
Equation (10) represent the number of healthy Th-cells infected by sensitive viruses and healthy Th-cells
contaminated by actively infected macrophages (Mah,s), respectively. Observe that in the first one Vs
can be counteracted by fusion and co-receptor inhibitors, in the second one drugs cannot obstruct
Mah,s(t)-action.
Negative terms −k2
(
1 − urt(t)
)(
1 − uii(t)
)
T lh,s(t) is the number of infected cells that convert from
latently to actively infected. This process is counteract by reverse transcriptase and integrase inhibitors
which inhibit reverse transcription and integration of viral DNA respectively. This element appears with
a positive sign in Equation (11) for actively Th-cells infected by sensitive viruses.
The negative contribute−isIe(t)T ah,s(t) is a novelty of our model, it represents the number of actively
infected naive T cells (T ah,s) killed by CTL effectors (I
e), at a constant rate is. We assume this number to
be proportional to the number of immune effectors (Ie).
Similar considerations can be observed for Equations (12) and (13) with the variation that there
isn’t any drug that can counteract resistant viruses. Moreover, the action of CTL effectors occurs at
a constant rate ir.
The dynamics for infected Ts cells are the following:
T˙ ls,s(t) = k1,s
(
1− ufi(t)
)(
1− uco(t)
)(
1−QTs,Vs
)
Vs(t)Ts(t) + k3M
a
h,s(t)Ts(t)
− k2
(
1− urt(t)
)(
1− uii(t)
)
T ls,s(t)− µT ls,sT ls,s(t) (14)
T˙ as,s(t) = k2
(
1− urt(t)
)(
1− uii(t)
)
T ls,s(t)− isIe(t)T as,s(t)− µTas,sT as,s(t) (15)
T˙ ls,r(t) = k1,r
(
1−QTs,Vr
)
Vr(t)Ts(t) + k3M
a
h,r(t)Ts(t)− k2T ls,r(t)− µT ls,rT ls,r(t) (16)
T˙ as,r(t) = k2T
l
s,r(t)− irIe(t)T as,r(t)− µTas,rT as,r(t) (17)
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The dynamics for infected Tr cells are the following:
T˙ lr,s(t) = k1,s
(
1− ufi(t)
)(
1− uco(t)
)(
1−QTr,Vs
)
Vs(t)Tr(t) + k3M
a
h,s(t)Tr(t)
− k2
(
1− urt(t)
)(
1− uii(t)
)
T lr,s(t)− µT lr,sT lr,s(t) (18)
T˙ ar,s(t) = k2
(
1− urt(t)
)(
1− uii(t)
)
T lr,s(t)− isIe(t)T ar,s(t)− µTar,sT ar,s(t) (19)
T˙ lr,r(t) = k1,r
(
1−QTr,Vr
)
Vr(t)Tr(t) + k3M
a
h,r(t)Tr(t)− k2T lr,r(t)− µT lr,rT lr,r(t) (20)
T˙ ar,r(t) = k2T
l
r,r(t)− irIe(t)T ar,r(t)− µTar,rT ar,r(t) (21)
The dynamics for infected Tg cells are the following:
T˙ lg,s(t) = k1,s
(
1− ufi(t)
)(
1− uco(t)
)(
1−QTg ,Vs
)
Vs(t)Tg(t) + k3M
a
h,s(t)Tg(t)
− k2
(
1− urt(t)
)(
1− uii(t)
)
T lg,s(t)− µT lg,sT lg,s(t) (22)
T˙ ag,s(t) = k2
(
1− urt(t)
)(
1− uii(t)
)
T lg,s(t)− isIe(t)T ag,s(t)− µTag,sT ag,s(t) (23)
T˙ lg,r(t) = k1,r
(
1−QTg ,Vr
)
Vr(t)Tg(t) + k3M
a
h,r(t)Tg(t)− k2T lg,r(t)− µT lg,rT lg,r(t) (24)
T˙ ag,r(t) = k2T
l
g,r(t)− irIe(t)T ag,r(t)− µTag,rT ag,r(t) (25)
As said for naive T lymphocytes (Th) the same holds for Equations (14)–(17) of Ts cells, for Equations
(18)–(21) of Tr cells and for Equations (22)–(25) of Tg cells.
The dynamics for infected macrophages are the following:
M˙ah,s(t) = k
M
1,s
(
1− urt(t)
)(
1− upi(t)
)
Vs(t)Mh(t)− µMah,sMah,s (26)
M˙ah,r(t) = k
M
1,rVr(t)Mh(t)− µMah,rMah,r (27)
We assumed that there is no latently infected macrophage population since the virus seems to
replicate once inside them. We also assume that macrophages produce virus at a slow constant
rate, sparing the host cell, so there is only natural death, not death by bursting like that for infected
T cells [14]. These equations present two infections rate, the former (kM1,s) related to sensitive viruses
(Vs), the latter related to resistant viruses (Vr).
Finally, we assume that reverse transcriptase and protease inhibitors can counteract macrophages
infected by sensitive viruses [15,16], while there are not drugs to counteract resistant viruses.
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The dynamics for sensitive (Vs) and resistant (Vr) viruses are the following:
V˙s(t) =
g
(
1− upi(t)
)
Vs(t)
b2 + Vs(t)
+ pis
(
1− upi(t)
)
uvs,s(t)
(
Mah,s(t) +
∑
T ai,s(t)
)
+ pir
(
1− upi(t)
)(
1− uvr,r(t)
)(
Mah,r(t) +
∑
T ai,r(t)
)
− k1,s ρs
(
1− ufi(t)
)(
1− uco(t)
)[∑
Ti(t)
(
1−QTi,Vs
)]
Vs(t)
− kM1,s ρs
(
1− urt(t)
)(
1− upi(t)
)
Mh(t)Vs(t)
− (s′sTg(t) + p′sTs(t))Vs(t)µVsVs(t)− µVsVs(t) (28)
V˙r(t) =
gVr(t)
b2 + Vr(t)
+ pis
(
1− uvs,s(t)
)(
Mah,s(t) +
∑
T ai,s(t)
)
+ piru
v
r,r(t)
(
Mah,r(t) +
∑
T ai,r(t)
)
− k1,r ρr
[∑
Ti(t)
(
1−QTi,Vr
)]
Vr(t)
− kM1,r ρr MhVr(t) −
(
s′rTg(t) + p
′
rTr(t)
)
Vr(t)− µVrVr(t) (29)
The term:
g
(
1− upi(t)
)
Vs(t)
b2 + Vs(t)
in the sensitive viruses Equation (28) is a source of virus that accounts for viral contributions to the
plasma from both external compartments, such as the lymph system, as well as virus produced by
infected cells in the plasma [17]. This source is counteracted by the protease inhibitors therapy upi(t).
The term:
pis
(
1− upi(t)
)
uvs,s(t)
(
Mah,s(t) +
∑
T ai,s(t)
)
represents the growth of sensitive viruses at a constant rate pis. This growth is counteracted by protease
inhibitors, and it is proportional to the number of actively infected cells contaminated by sensitive viruses
and to the mutation rate from sensitive to other sensitive viruses (uvs,s). Finally:
pir
(
1− upi(t)
)(
1− uvr,r(t)
)(
Mah,r(t) +
∑
T ai,r(t)
)
represents the growth (at a constant rate pir) of resistant viruses that mutate into sensitive viruses (at a
rate 1− uvr,r = uvr,s). Also this growth is counteracted by protease inhibitors, and it is proportional to the
number of actively infected cells, contaminated by resistant viruses. Parameters b2, g, pis, pir are assumed
positive and constant.
The negative contributions:
− k1,s ρs
(
1− ufi(t)
)(
1− uco(t)
)[∑
Ti(t)
(
1−QTi,Vs
)]
Vs(t)
− kM1,s ρs
(
1− urt(t)
)(
1− upi(t)
)
Mh(t)Vs(t)
indicate that viruses which infect lymphocytes are not free to circulate in the blood, and so they can not
infect other cells at the same time. The constant ρs indicates the average number of sensitive virions
infecting a cell: in our numerical simulations we set this number equal to 1, but the model permits also
other values for this parameter, that is a cell could be infected by several viruses.
The last term:
− (s′sTg(t) + p′sTs(t))Vs(t)
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represents the number of sensitive virions blocked by specific immune response (represented by Ts cells)
and by unspecific immune response (represented by Tg cells).
For what concerns resistant viruses dynamics Equation (28), considerations are the same just seen for
sensitive viruses, with the only difference that protease inhibitors can not counteract Vr.
The boundary conditions include the initial states:
Th(t0) = T
0
h Ts(t0) = T
0
s Tr(t0) = T
0
r
Tg(t0) = T
0
g Mh(t0) =M
0
h I
p(t0) = I
p
0
Ie(t0) = I
e
0 T
l
h,s(t0) = T
l,0
h,s T
a
h,s(t0) = T
a,0
h,s
T lh,r(t0) = T
l,0
h,r T
a
h,r(t0) = T
a,0
h,r T
l
s,s(t0) = T
l,0
s,s
T as,s(t0) = T
a,0
s,a T
l
s,r(t0) = T
l,0
s,r T
a
s,r(t0) = T
a,0
s,r
T lr,s(t0) = T
l,0
r,s T
a
r,s(t0) = T
a,0
r,s T
l
r,r(t0) = T
l,0
r,r
T ar,r(t0) = T
a,0
r,r T
l
g,s(t0) = T
l,0
g,s T
a
g,s(t0) = T
a,0
g,s
T lg,r(t0) = T
l,0
g,r T
a
g,r(t0) = T
a,0
g,r M
a
h,s(t0) =M
a,0
h,s
Mah,r(t0) =M
a,0
h,r Vs(t0) = V
0
s Vr(t0) = V
0
r (30)
and the final values:
Ti(tf ),Mh(tf ), I
p(tf ), I
e(tf ), T
l
i,j(tf ), T
a
i,j(tf ), Vj(tf ) ∈ R+ (31)
Each therapy control, that represents the various drugs dosage, is assumed to vary within the range
[0, 1], the same holds for the HIV-controls, which represent the mutation rates of viruses, so that:
u1(t) ∈ [0, 1]6, u2(t) ∈ [0, 1]2 (32)
and recalling the control u2(t) definition, we have:
uvs,s(t) + u
v
s,r(t) = 1, u
v
r,r(t) + u
v
r,s(t) = 1 (33)
Summarizing, the payoffs Equations (1) and (2) together with the associated state functions
Equations (3)–(29) and with the constraints Equations (30)–(33) constitute a differential game
characterized by:
• 27 state variables (Table 1);
• 8 controls (Table 2): 6 controls for the therapy and 2 controls for the virus;
• 98 parameters (Tables 3 and 4).
3. Open Loop Nash Equilibrium
In line with [6], we look for an Open Loop Nash equilibrium of the HIV/therapy game, considering the
Pontryagin Maximum Principle necessary conditions. The model is difficult to analyze due to the number
of variables and constraints and to the fact that state and co-state equations are “coupled”. For the sake
of simplicity, let us relax the non negativity constraints Equation (31) on the state variables and verify
them ex post, assuming that:
Ti(tf ),Mh(tf ), I
p(tf ), I
e(tf ), T
l
i,j(tf ), T
a
i,j(tf ), Vj(tf ) ∈ R (34)
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Theorem 1. [Therapy equilibrium necessary conditions] The optimal Therapy control satisfies the
following necessary conditions:
u∗1(t) =
(
u∗co(t), u
∗
fi(t), u1
∗
ib(t), u
∗
ii(t), u
∗
pi(t), u
∗
rt(t)
) ∈ {0, 1, uˆ1(t)} (35)
where uˆ1(t) is the unique stationary point of the Therapy Hamiltonian Equation (A2). The co-states
functions λ1(t) satisfy the co-state equations:
λ˙1,k(t) = −∂HTher
∂xk
(
x, u1, λ1,1, λ1,2, . . . , λ1,27, t
)
, k = 1, . . . , 27 (36)
with transversality conditions
λ1,k(tf ) = 0, k = 1, . . . , 27 (37)
The Therapy Hamiltonian is not necessarily concave w.r.t. its controls, nevertheless, some specific
values of the model parameters lead to concavity, as the following Theorem states.
Theorem 2. [Therapy Hamiltonian Concavity sufficient conditions] If:
Aco Afi − h21,2(t) > 0 (38)
and:
Aib ·
[
Art Api Aii − h24,6(t) Api − h25,6(t) Aii
]
> 0 (39)
where h1,2(t), h4,6(t) and h5,6(t) are given by Equations (A10)–(A12) respectively, then the Therapy
Hamiltonian function is concave in u1.
Proof. See Appendix A.
If concavity holds, the necessary conditions for the Therapy control Equation (35) takes the form:
u∗1(t) = min
{
1,max{0, uˆ1(t)}
}
(40)
where uˆ1(t) is the unique stationary point of the Therapy player.
Something more specific can be said for the HIV equilibrium strategies.
Theorem 3. [HIV equilibrium necessary conditions] The HIV mutation rates satisfy the following
necessary conditions u∗2(t) = (u
v∗
s,s(t), u
v∗
r,r(t)), where:
uv
∗
s,s(t) = min{1,max{0, uˆvs,s(t)}}, uv
∗
r,r(t) = min{1,max{0, uˆvr,r(t)}} (41)
and:
uˆvs,s(t) =
Bs,r − pis
(
Mah,s(t) +
∑
T ai,s(t)
)(
λ2,27(t) + λ2,26(t)
(− 1 + upi(t)))
Bs,r
uˆvr,r(t) =
Br,s − pir
(
Mah,r(t) +
∑
T ai,r(t)
)(
λ2,27(t) + λ2,26(t)
(− 1 + upi(t)))
Br,s
(42)
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The functions λ2,26(t) and λ2,27(t) are the co-states associated to the HIV virus variables Vs and Vr
respectively. More generally the co-state equations are:
λ˙2,k(t) = −∂HHIV
∂xk,
(
x, u2, λ2,1, λ2,2, . . . , λ2,27, t
)
, k = 1, . . . , 27, (43)
with transversality conditions:
λ2,k(tf ) = 0, k = 1, . . . , 27. (44)
Proof. See Appendix A.
Observe that, due to the transversality conditions, it straight follows that uv∗s,s(tf ) = u
v∗
r,r(tf ) = 1,
so that by Equation (33) we obtain that in equilibrium condition the virus mutation rates from sensitive
viruses to resistant viruses and vice versa vanish, that is uv∗s,r(tf ) = u
v∗
r,s(tf ) = 0. Although it might
appear as negative the fact that resistant viruses do not turn to sensitive any more, we must underline
that this happens at the final time, when the number of viruses is sensibly decreased and a consequent
long life expectancy has been obtained. In fact, our aim is to determine a therapy capable to prevent viral
replication with its related side effects.
Substituting the optimal controls in the state Equations (3)–(29) and in the co-state Equations (36)
and (43), together with Equations (30), (37) and (44), we obtain a system of 81 autonomous strongly
non linear first order differential equations, more precisely
• 27 equations on the states;
• 54 equations on the adjoint variables;
• 27 boundary conditions for the states at time t0;
• 54 boundary conditions for the adjoint variables at time tf .
4. Numerical Simulations
An analytical solution of the state/co-state system can be obtained through a symbolic software,
like for example, Wolfram Mathematica, nevertheless such a solution turns out to be as much long
as uninformative. So that a numerical resolution turns out to be crucial in order to get some enlightening
results. We formulate and apply an efficient and intuitive algorithm by combining the Forward-Backward
Sweep algorithm [18–21] and a 4th order Runge-Kutta routine (see e.g., [22]). We performed several
simulations and we always got a unique solution to the necessary conditions. In what follows we present
two particular instances, using the most common parameter values cited in the related literature, (see
Appendix B). Please observe that differently from the theoretical analysis, here the HIV mutation rates
uvr,s and u
v
s,r are explicitly shown, simply for an interpretation point of view.
4.1. Concave Instance
We first present a situation where the therapy Hamiltonian is concave, that is if conditions
Equations (38) and (39) hold. Such instance is characterized by very effective although highly toxic
drugs which significantly reduce the virus mutation rates uvr,s and u
v
s,r.
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In Figure 1, the first six graphs represent therapy dosages, the last two graphs show the HIV mutations,
and the table shows the optimal payoffs related to immune system-therapy and to HIV, respectively.
Coreceptor antagonist (uco) and fusion inhibitors (ufi) are both used for interfering with binding,
fusion and entry of HIV to the host cell. Their dosages are the same for all therapy period (1000 days),
more precisely they are administered at maximum doses for a few days and then they are no
longer employed.
Immune boosting drugs (uib) were introduced into this type of dynamics by Joshi in 2006 [12].
They represent the drugs that increase immune defenses enhancing the number of cells of immune
system. In Joshi’s studies these drugs are used at a very low constant level (around 0.02) for the first
50 days. In our simulations, such a value turns out to be constantly equal to zero and this may have two
explanations: first of all, it is not necessary to administrate a high toxicity drug if the lymphocyte counts
remains high enough (around 800–900 cells/mm3), (see Figure 2). Secondarily, increasing the number
of T lymphocytes means increasing the number of target cells for HIV virus, thus risking an increase in
viral replication.
Figure 1. Equilibrium strategies and payoffs (concave instance).
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Figure 2. Lymphocytes, macrophage, and CTL dynamics (concave instance).
As we expected, Integrase (uii) and Reverse Transcriptase Inhibitors (urt) have very similar optimal
dosages, because they are both used in the same phase of virions creation. To be more accurate, Reverse
Transcriptase Inhibitors are used at the highest level for a few more days, in fact the interaction between
the two enzymes, integrase (IN) and reverse transcriptase (RT) is functional and plays an important
role in replication of the virus. Evidence has been accumulating that IN not only interacts closely
with RT during reverse transcription but also remains associated with RT during the formation of the
preintegrative complex.
Protease inhibitors drugs (upi) block the viral protease enzyme necessary to produce mature virions
upon budding from the host membrane. These drugs are used at maximum level for about the first
350 days, then the dosage decreases gradually becoming zero the last 100 days.
In fact it is well known that the resistance to protease inhibitors is a stepwise process. Briefly,
primary mutations often have only a small effect on resistance, so that the PI therapy persists longer.
Conversely, during continuous PI therapy, additional mutations emerge in the protease (commonly
referred to as secondary mutations) leading to high-level PI resistance. These secondary mutations
often have only a minor effect on drug susceptibility if they appear all alone but, in the presence of
primary mutations, they can lead to a drastic increase in resistance, with the consequent decrease of the PI
therapy, [23].
For what concerns HIV, the resistant–to–sensitive mutation rate from (uvr,s) is maximum for the
first 350 days, then it drastically decreases, thanks to drug effects. At the same instant, the
sensitive-to-resistant virus mutation rate (uvs,r), which is initially null, moves to the maximum level,
because of the virus survival tendency. Nevertheless it does not remain at the maximum level, it begins
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to decrease, (around day 550) thanks to the protease inhibitors effect (upi). At the end of the planning
interval both the virus mutation rates vanish, as observed in Section 3 after Theorem 3. The Therapy and
HIV payoffs are listed in the lower part of Figure 1. Observe that the high toxicity of drugs causes high
costs for the immune system, and leads to low payoff values.
The white blood cell count is one of the most important tests to verify the presence of the HIV virus.
It is an indicator of the health status of a patient and is one of the key factors in determining when to start
HAART and prophylaxis for opportunistic infections. The tests usually measure the white blood cells
present in the sample and calculate the percentage of CD4+ T lymphocytes. This value can be variable
among different individuals and influenced by several factors. In general, the percentage of CD4+ T-cells
is stable and it can be a parameter for evaluating the immune functions of a patient. Usually, it has a
level between 500 and 1000 cells/cm3 in a healthy patient, and if it goes below this threshold, a possible
infection could appear and damage the immune system. Observe that, despite the high toxicity of drugs,
the lymphocyte count is sufficiently high (around 800–900 cells/mm3,) for the entire time interval (see
Figure 2).
In Figures 2–4 are shown the dynamics of all the 27 state variables of the model. In particular, in
Figure 2 we find the dynamics of various types of healthy immune cells and in Figure 3 we find the
infected cells dynamics. Finally in Figure 4 we find the dynamics of sensitive (Vs) and resistant viruses
(Vr). Note that all optimal state functions are positive, so that the non-negativity constraints are fully
satisfied. Sensitive viruses population decreases right from the start, under the effects of the therapy, and
it becomes almost zero around day 400. Resistant viruses have the same behaviour and they become
zero around day 800.
Figure 3. Infected cells dynamics (concave instance).
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Figure 4. Sensitive and resistant viruses dynamics (concave instance).
4.2. Nonconcave Instance
Let us now consider a nonconcave therapy instance, characterized by drugs with low toxicity but not
very effective. In Figure 5, we can observe a prolonged intake over time is required. The performed
algorithm is stable, in fact, results do not vary with the initial values given to adjoint variables at time t0
(as it happens for other studies of the related literature, see e.g., [19,20]). Computational time is about
15–60 min in an Intel(R) core(TM) i-7 4.700 HQ CPU, 2.40 GHz.
HIV mutation rate uvr,s is maximum for the first 20 days then it decreases thanks to the combined
action of therapy controls uco, ufi and upi. The reduction of uvr,s involves the immediate increase of the
sensitive-to-resistant viruses mutation rate (uvs,r) to the maximum level. This causes the necessity to
use the controls uii and urt at the highest level till day 250 in order to reduce to zero mutations uvs,r.
Thanks to the prolonged therapy the latter remain at that null level until the end of the considered time
interval. HIV attempts a further sting in the tail, by increasing the rate of mutation uvr,s to the highest
level. In the meantime controls uii and urt are brought to zero for a small time interval, while the controls
uco, ufi and upi continue to be used at their maximum level. Until the control uvr,s remains at a high level,
the controls uii and urt perform a gradual increase.
We can observe how the combined action of 5 drugs leads to a decrease of the mutation rate uvr,s,
around day 700. It continues to decrease for the remaining 300 days, after which both the viruses
mutation rates are null. Immune boosting (uib) continues to have a null dosage, for the same reasons
seen in the concave instance.
The payoff for therapy and HIV are listed in the lower part of Figure 5. Due to the low toxicity of the
drugs, the optimal immune system-therapy payoff turns to greater w.r.t. the one obtained in the concave
instance, whilst the HIV payoff turns to be lower.
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Figure 5. Equilibrium strategies and payoffs (nonconcave instance).
In Figures 6–8 we report the dynamics of all 27 variable states. Note again that all optimal state
functions are positive, so that the non-negativity constraints are fully satisfied. Although the drugs are not
so effective, the lymphocytes count is high (around 800–900 cells/mm3). Sensitive viruses population
(Vs) becomes null around day 300, while resistant viruses population (Vr) goes to zero after 900 days.
Figure 6. Lymphocytes, macrophage and CTL dynamics (nonconcave instance).
Mathematics 2015, 3 1159
Figure 7. Infected cells dynamics (nonconcave instance).
Figure 8. Sensitive and resistant viruses dynamics (nonconcave instance).
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5. Conclusions
We have considered the game theory approach in a medical-therapeutic context for HIV treatment.
We have formulated a differential game which describes the interaction between the immune system of
a patient and the virus action. In order to model the efficient HAART therapy, we have considered 27
state functions and eight controls (six for the therapy and two for HIV). We look for an open Loop Nash
equilibrium in order to find a stable long-term coexistence between the two players.
The optimality necessary conditions lead to a system of 81 first order strongly non-linear differential
equations. Once proved the existence and uniqueness of the solution of such a system, we have
performed some numerical simulations in order to get enlightening results. Just for explanatory
examples, we considered two specific instances. Mathematically speaking the two instances differ in
the concavity properties of the Hamiltonians w.r.t. the related controls. From the medical point of
view, the concave instance is characterized by very effective although highly toxic drugs, whereas the
nonconcave instance is represented by low effective and moderately toxic drugs. We observe quite
different behaviours in the therapy strategies according to the type of drugs used. And this, in our
opinion, is very interesting, as our aim is to find a tool which can support the clinician when combining
the different drugs in the HAART therapy. Having an idea of the dynamical reactions to a given
biological effect can help to make the optimal therapeutic decision.
An immediate, although not trivial, prospect could be the analysis of the problem following the
Hamilton-Jacobi-Bellman approach to find a time consistent Markovian Nash equilibrium [24].
Another possible further extension of this model could be obtained in matching the Game Theory
approach with the Fuzzy system issue [25–28], paying attention to the unavoidable complexity increase.
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Appendix
A. Nash Equilibria
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In this Appendix we report the proofs of Theorems 1 and 2. We first introduce the Hamiltonian
functions for the two players in order to make the proofs easier to be read, see [29]. The Therapy
Hamiltonian is:
HTher
(
x, u1, λ1,1, λ1,2, . . . , λ1,27, t
)
= λ1,0
{
Mh(t) + I
p(t) + Ie(t) +
∑
∀i∈Γ
Ti(t)− 1
2
∑
∀k∈Ω
Aku
2
k
}
+ λ1,1
{
s1,ThθTh
θTh +
(
Vs + Vr
)+ rTh
(
1−
∑
Ti +
∑
T li,j +
∑
Tai,j
Tmax
)
+ uibTh
− k1,s
(
1− ufi
)(
1− uco
)(
1−QTh,Vs
)
VsTh − µThTh − k1,r
(
1−QTh,Vr
)
VrTh − k
(
Vs + Vr
)
Th
− k′(Vs + Vr)Th − k3(Mah,s +Mah,r)Th
}
+ λ1,2
{
kVsTh + uibTs − µTsTs − k1,s
(
1− ufi
)(
1− uco
)(
1−QTs,Vs
)
VsTs
− k1,r
(
1−QTs,Vr
)
VrTs − k3
(
Mah,s(t) +M
a
h,r
)
Ts
}
+ λ1,3
{
kVrTh + uibTr − µTrTr − k1,s
(
1− ufi
)(
1− uco
)(
1−QTr,Vs
)
VsTr
− k1,r
(
1−QTr,Vr
)
VrTr − k3
(
Mah,s +M
a
h,r
)
Tr
}
+ λ1,4
{
k′
(
Vs + Vr
)
Th + uibTg − µTgTg
}
+ λ1,5
{
s1,Mh − µMhMh − kM1,s
(
1− urt
)(
1− upi
)
VsMh − kM1,rVrMh
}
+ λ1,6
{
cIp
∑
Ti
∑
Tai,j − cqIp
∑
Tai,j − µIpIp
}
+ λ1,7
{
cqIp
∑
Tai,j − µIeIe
}
+ λ1,8
{
k1,s
(
1− ufi
)(
1− uco
)(
1−QTh,Vs
)
VsTh + k3M
a
h,sTh(t)− µT l
h,s
T lh,s − k2
(
1− urt
)(
1− uii
)
T lh,s
}
+ λ1,9
{
k2
(
1− urt
)(
1− uii
)
T lh,s − µTah,sT
a
h,s − isIeTah,s
}
+ λ1,10
{
k1,r
(
1−QTh,Vr
)
VrTh + k3M
a
h,rTh − µT l
h,r
T lh,r − k2T lh,r
}
+ λ1,11
{
k2T
l
h,r − µTah,rT
a
h,r − irIeTah,r
}
+ λ1,12
{
k1,s
(
1− ufi
)(
1− uco
)(
1−QTs,Vs
)
VsTs + k3M
a
h,sTs − µT ls,sT
l
s,s − k2
(
1− urt
)(
1− uii
)
T ls,s
}
+ λ1,13
{
k2
(
1− urt
)(
1− uii
)
T ls,s − µTas,sTas,s − isIeTas,s
}
+ λ1,14
{
k1,r
(
1−QTs,Vr
)
VrTs + k3M
a
h,rTs − µT ls,rT
l
s,r − k2T ls,r
}
+ λ1,15
{
k2T
l
s,r − µTas,rTas,r − irIeTas,r
}
+ λ1,16
{
k1,s
(
1− ufi
)(
1− uco
)(
1−QTr,Vs
)
VsTr + k3M
a
h,sTr − µT lr,sT
l
r,s − k2
(
1− urt
)(
1− uii
)
T lr,s
}
+ λ1,17
{
k2
(
1− urt
)(
1− uii
)
T lr,s − µTar,sTar,s − isIeTar,s
}
+ λ1,18
{
k1,r
(
1−QTr,Vr
)
VrTr + k3M
a
h,rTr − µT lr,rT
l
r,r − k2T lr,r
}
+ λ1,19
{
k2T
l
r,r − µTar,rTar,r − irIeTar,r
}
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+ λ1,20
{
k1,s
(
1− ufi
)(
1− uco
)(
1−QTg,Vs
)
VsTg + k3M
a
h,sTg − µT lg,sT
l
g,s − k2
(
1− urt
)(
1− uii
)
T lg,s
}
+ λ1,21
{
k2
(
1− urt
)(
1− uii
)
T lg,s − µTag,sTag,s − isIeTag,s
}
+ λ1,22
{
k1,r
(
1−QTg,Vr
)
VrTg + k3M
a
h,rTg − µT lg,rT
l
g,r − k2T lg,r
}
+ λ1,23
{
k2T
l
g,r − µTag,rTag,r − irIeTag,r
}
+ λ1,24
{
kM1,s
(
1− urt
)(
1− upi
)
VsMh − µMa
h,s
Mah,s
}
+ λ1,25
{
kM1,rVrMh − µMah,rM
a
h,r
}
+ λ1,26
{
g
(
1− upi
)
Vs
b2 + Vs
+ pis
(
1− upi
)
uvs,s
(
Mah,s +
∑
Tai,s
)
+ pir
(
1− upi
)(
1− uvr,r
)(
Mah,r +
∑
Tai,r
)
− k1,s ρs
(
1− ufi
)(
1− uco
)[∑
Ti
(
1−QTi,Vs
)]
Vs
− kM1,s ρs
(
1− urt
)(
1− upi
)
MhVs − µVsVs −
(
s′sTg + p
′
sTs
)
Vs
}
+ λ1,27
{
gVr
b2 + Vr
+ piru
v
r,r
(
Mah,r +
∑
Tai,r
)
+ pis
(
1− uvs,s
)(
Mah,s +
∑
Tai,s
)
− k1,r ρr
[∑
Ti
(
1−QTi,Vr
)]
Vr − kM1,r ρr MhVr − µVrVr −
(
s′rTg + p
′
rTr
)
Vr
}
(A1)
The HIV Hamiltonian is
HHIV
(
x, u2, λ2,1, λ2,2, . . . , λ2,27, t
)
= λ2,0
{
Vs + Vr +
∑
∀i∈Γ ∀j∈Θ
(
T li,j + T
a
i,j
)− 1
2
(
Bs,r
(
1− uvs,s
)2
+Br,s
(
1− uvr,r
)2)}
+ λ2,1
{
s1,ThθTh
θTh +
(
Vs + Vr
)+ rTh (1− ∑Ti +∑T li,j +∑T ai,j
Tmax
)
+ uibTh
− k1,s
(
1− ufi
)(
1− uco
)(
1−QTh,Vs
)
VsTh − µThTh − k1,r
(
1−QTh,Vr
)
VrTh
− k(Vs + Vr)Th − k′(Vs + Vr)Th − k3(Mah,s +Mah,r)Th
}
+ λ2,2
{
kVsTh + uibTs − µTsTs − k1,s
(
1− ufi
)(
1− uco
)(
1−QTs,Vs
)
VsTs
− k1,r
(
1−QTs,Vr
)
VrTs − k3
(
Mah,s(t) +M
a
h,r
)
Ts
}
+ λ2,3
{
kVrTh + uibTr − µTrTr − k1,s
(
1− ufi
)(
1− uco
)(
1−QTr,Vs
)
VsTr
− k1,r
(
1−QTr,Vr
)
VrTr − k3
(
Mah,s +M
a
h,r
)
Tr
}
+ λ2,4
{
k′
(
Vs + Vr
)
Th + uibTg − µTgTg
}
+ λ2,5
{
s1,Mh − µMhMh − kM1,s
(
1− urt
)(
1− upi
)
VsMh − kM1,rVrMh
}
+ λ2,6
{
cIp
∑
Ti
∑
T ai,j − cqIp
∑
T ai,j − µIpIp
}
+ λ2,7
{
cqIp
∑
T ai,j − µIeIe
}
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+ λ2,8
{
k1,s
(
1− ufi
)(
1− uco
)(
1−QTh,Vs
)
VsTh + k3M
a
h,sTh(t)− µT lh,sT
l
h,s − k2
(
1− urt
)(
1− uii
)
T lh,s
}
+ λ2,9
{
k2
(
1− urt
)(
1− uii
)
T lh,s − µTah,sT ah,s − isIeT ah,s
}
+ λ2,10
{
k1,r
(
1−QTh,Vr
)
VrTh + k3M
a
h,rTh − µT lh,rT
l
h,r − k2T lh,r
}
+ λ2,11
{
k2T
l
h,r − µTah,rT ah,r − irIeT ah,r
}
+ λ2,12
{
k1,s
(
1− ufi
)(
1− uco
)(
1−QTs,Vs
)
VsTs + k3M
a
h,sTs − µT ls,sT ls,s − k2
(
1− urt
)(
1− uii
)
T ls,s
}
+ λ2,13
{
k2
(
1− urt
)(
1− uii
)
T ls,s − µTas,sT as,s − isIeT as,s
}
+ λ2,14
{
k1,r
(
1−QTs,Vr
)
VrTs + k3M
a
h,rTs − µT ls,rT ls,r − k2T ls,r
}
+ λ2,15
{
k2T
l
s,r − µTas,rT as,r − irIeT as,r
}
+ λ2,16
{
k1,s
(
1− ufi
)(
1− uco
)(
1−QTr,Vs
)
VsTr + k3M
a
h,sTr − µT lr,sT lr,s − k2
(
1− urt
)(
1− uii
)
T lr,s
}
+ λ2,17
{
k2
(
1− urt
)(
1− uii
)
T lr,s − µTar,sT ar,s − isIeT ar,s
}
+ λ2,18
{
k1,r
(
1−QTr,Vr
)
VrTr + k3M
a
h,rTr − µT lr,rT lr,r − k2T lr,r
}
+ λ2,19
{
k2T
l
r,r − µTar,rT ar,r − irIeT ar,r
}
+ λ2,20
{
k1,s
(
1− ufi
)(
1− uco
)(
1−QTg,Vs
)
VsTg + k3M
a
h,sTg − µT lg,sT lg,s − k2
(
1− urt
)(
1− uii
)
T lg,s
}
+ λ2,21
{
k2
(
1− urt
)(
1− uii
)
T lg,s − µTag,sT ag,s − isIeT ag,s
}
+ λ2,22
{
k1,r
(
1−QTg,Vr
)
VrTg + k3M
a
h,rTg − µT lg,rT lg,r − k2T lg,r
}
+ λ2,23
{
k2T
l
g,r − µTag,rT ag,r − irIeT ag,r
}
+ λ2,24
{
kM1,s
(
1− urt
)(
1− upi
)
VsMh − µMah,sMah,s
}
+ λ2,25
{
kM1,rVrMh − µMah,rMah,r
}
+ λ2,26
{
g
(
1− upi
)
Vs
b2 + Vs
+ pis
(
1− upi
)
uvs,s
(
Mah,s +
∑
T ai,s
)
+ pir
(
1− upi
)(
1− uvr,r
)(
Mah,r +
∑
T ai,r
)
− k1,s ρs
(
1− ufi
)(
1− uco
)[∑
Ti
(
1−QTi,Vs
)]
Vs
− kM1,s ρs
(
1− urt
)(
1− upi
)
MhVs − µVsVs −
(
s′sTg + p
′
sTs
)
Vs
}
+ λ2,27
{
gVr
b2 + Vr
+ piru
v
r,r
(
Mah,r +
∑
T ai,r
)
+ pis
(
1− uvs,s
)(
Mah,s +
∑
T ai,s
)
− k1,r ρr
[∑
Ti
(
1−QTi,Vr
)]
Vr − kM1,r ρr MhVr − µVrVr −
(
s′rTg + p
′
rTr
)
Vr
}
(A2)
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The Hamiltonian functions of the two players are both almost twice differentiable with respect to
the related controls and admit a unique stationary point. The maximization of the Hamiltonians is
guarantee by Weierstrass Theorem, thanks to their continuity and the compactness of the feasible sets
for the controls.
Proof of Theorem 1. The partial derivatives of the Therapy Hamiltonian w.r.t. the related controls are
∂HTher
∂uco
= −Acouco − k1,s
(− 1 + ufi)Vs
·
[
(−1 +QTg,Vs)λ1,20Tg − (−1 +QTg,Vs)λ1,4Tg − (−1 +QTh,Vs)
(
λ1,1 − λ1,8
)
Th
+ (−1 +QTr,Vs)
(
λ1,16 − λ1,3
)
Ts + (−1 +QTs,Vs)
(
λ1,12 − λ1,2
)
Ts
+ ρsλ1,26
(
Tg −QTg,VsTg + Th −QTh,VsTh + Tr −QTr,VsTr + Ts −QTs,VsTs
)]
(A3)
∂HTher
∂ufi
= −Afiufi − k1,s
(− 1 + uco)Vs
·
[
(−1 +QTg,Vs)λ1,20Tg − (−1 +QTg,Vs)λ1,4Tg − (−1 +QTh,Vs)
(
λ1,1 − λ1,8
)
Th
+ (−1 +QTr,Vs)
(
λ1,16 − λ1,3
)
Ts + (−1 +QTs,Vs)
(
λ1,12 − λ1,2
)
Ts
+ ρsλ1,26
(
Tg −QTg,VsTg + Th −QTh,VsTh + Tr −QTr,VsTr + Ts −QTs,VsTs
)]
(A4)
∂HTher
∂uib
= λ1,4Tg + λ1,1Th + λ1,3Tr + λ1,2Ts −Aibuib (A5)
∂HTher
∂uii
= −Aiiuii − k2
(− 1 + urt)
·
[(
λ1,20 − λ1,21
)
T lg,s +
(
λ1,8 − λ1,9
)
T lh,s +
(
λ1,16 − λ1,17
)
T lr,s +
(
λ1,12 − λ1,13
)
T ls,s
]
(A6)
∂HTher
∂upi
= Apiupi + k
M
1,s
(
λ1,24 − λ1,5
)
Mh
(− 1 + urt)Vs
+ λ1,26
{
pir
(
Mah,r + T
a
g,r + T
a
h,r + T
a
r,r + T
a
s,r
) · (− 1 + uvr,r)
− pisuvs,s
(
Mah,r + T
a
g,r + T
a
h,r + T
a
r,r + T
a
s,r
)
+ Vs
[
− kM1,sρsMh
(− 1 + urt)− g
b2 + Vs
]}
(A7)
∂HTher
∂urt
= k2
(− 1 + uii)[(λ1,20 − λ1,21)T lg,s + (λ1,8 − λ1,9)T lh,s + (λ1,16 − λ1,17)T lr,s + (λ1,12 − λ1,13)T ls,s]
− Arturt + kM1,sMhVs
(− 1 + upi)(λ1,24 − pisλ1,26 − λ1,5) (A8)
There exists a unique Therapy stationary point, nevertheless we do not report it because of the length
of its analytical formula.
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The 6× 6 Therapy Hessian matrix w.r.t. its controls is
H˜′′Ther =

−Aco h1,2(t) 0 0 0 0
h1,2(t) −Afi 0 0 0 0
0 0 −Aib 0 0 0
0 0 0 −Aii 0 h4,6(t)
0 0 0 0 −Api h5,6(t)
0 0 0 h4,6(t) h5,6(t) −Art

(A9)
where
h1,2(t) = k1,sVs(t)
{
(QTh,Vs − 1)
(
λ1,1(t)− λ1,8(t)
)
Th(t)− (QTs,Vs − 1)
(
λ1,12(t)− λ1,2(t)
)
Ts(t)
− (QTr,Vs − 1)
(
λ1,16(t)− λ1,3(t)
)
Tr(t)− (QTg,Vs − 1)
(
λ1,20(t)− λ1,4(t)
)
Tg(t)
+ ρsλ1,26(t)
[
(QTh,Vs − 1)Th(t) + (QTs,Vs − 1)Ts(t) + (QTr,Vs − 1)Tr(t) + (QTg,Vs − 1)Tg(t)
]}
(A10)
h4,6(t) = k2
[(− λ1,12(t) + λ1,13(t))T ls,s(t) + (− λ1,16(t) + λ1,17(t))T lr,s(t)
+
(− λ1,20(t) + λ1,21(t))T lg,s(t) + (− λ1,8(t) + λ1,9(t))T lh,s(t)] (A11)
h5,6(t) = k
M
1,s
(
λ1,24(t)− ρsλ1,26(t)− λ1,5(t)
)
Vs(t)Mh(t) (A12)
As the first leading principal minor (−Aco) is negative, the matrix cannot be in any case positively
or semi-positively defined, so that the unique stationary point can be either a a saddle point or a local
maximum. In the former case, one of the two extremes of the control feasible set is the maximum
point. In the latter case, we must evaluate the Hamiltonian function not only in the extremes of the
feasible control set but also in the stationary point, getting the point with the maximum objective value.
In both case Equation (35) holds. The function evaluation necessary to determine the optimal Therapy
control can be performed by mean of the numerical quadrature formulas with three different methods
of numerical integration: the Composite rectangle method, the Composite trapezoid method; and the
Composite Cavalieri-Simpson method, see [22].
Proof of Theorem 2. Let Equations (38) and (39) hold, then the leading principal minors of the Therapy
Hessian matrix are the following
2th order
det H˜′′Ther,2 = Aco Afi − h21,2(t) > 0
3rd order
−Aib · det H˜′′Ther,2 < 0
4th order
Aii · Aib · det H˜′′Ther,2 > 0
5th order
−Api · Aii · Aib · det H˜′′Ther,2 < 0
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Finally the determinant of the Hessian matrix, (principal minor of 6th order), is
det(H˜′′Ther) = det H˜
′′
Ther,2 · Aib ·
[
Art Api Aii − h24,6(t) Api − h25,6(t) Aii
]
> 0
The Hessian matrix is negative definite, viz the Therapy Hamiltonian function is concave in u1.
Proof of Theorem 3. The partial derivatives of the HIV Hamiltonian w.r.t. the related controls are
∂HHIV
∂uvs,s
= pis
(
Mah,s(t) + T
a
g,s(t) + T
a
h,s(t) + T
a
r,s(t) + T
a
s,s(t)
)
·
(
λ2,27(t) + λ2,26(t)
(− 1 + upi(t)))−Bs,r(− 1 + uvs,s(t)) (A13)
∂HHIV
∂uvr,r
= pir
(
Mah,r + T
a
g,r + T
a
h,r + T
a
r,r + T
a
s,r
)
·
(
λ2,27 + λ2,26
(− 1 + upi))−Br,s(− 1 + uvr,r) (A14)
they admit a unique HIV stationary point, namely Equation (42). The HIV Hessian matrix is
H˜′′HIV =
(
−Bs,r 0
0 −Br,s
)
(A15)
it is negative definite, because Bs,r, Br,s > 0, therefore the HIV Hamiltonian function is strictly concave
in its controls uvs,s(t) and u
v
r,r(t), and so the necessary conditions for the optimal controls are given by
Equation (41).
B. Parameters
The sets of parameter values we presented in the numerical Section 4 are very similar to the ones
most commonly used in the related literature [5]. The two instances mainly differ from each other for
the drugs toxicity parameters and HIV mutation costs, to consider concave and nonconcave properties.
Table B1 shows the values we assigned to drugs toxicity and mutation costs for each instance. Tables
B2 and B3 show all common parameter values for both instances. Finally Table B4 contains boundary
conditions.
Table B1. Weights.
Symbol Description Concave Instance Nonconcave Instance
Aco Coreceptor antagonists toxicity 5 10−2.7
Afi Fusion inhibitors toxicity 5 10−2.7
Aib Immune boosting toxicity 5 10−2.7
Aii Integrase inhibitors toxicity 5 10−2.7
Api Protease inhibitors toxicity 5 10−2.7
Art Reverse transcriptase inhibitors toxicity 5 10−2.7
Bs,r Mutation costs from sensitive to resistant viruses 10−10 10−13.7
Br,s Mutation costs from resistant to sensitive viruses 10−11 10−10.3
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Table B2. Common parameters at both instances (Part 1).
Symbol Description Value
b2 Half saturation constant 1 mm3
c Cytotoxic T Lymphocyte (CTL) activation rate 0.03 1day
g Input rate of external viral source 25 cellsmm3×day
is Death rate of cells infected by Vs due to immune response 10−2 1day
ir Death rate of cells infected by Vr due to immune response 5× 10−4 1day
k Rate Th convert to specific immune reaction cells (Ts or Tr) 10−6 1day
k′ Rate Th convert to unspecific immune reaction cells (Tg) 10−6 1day
k1,s Rate CD4 T cells becomes infected by Vs 0.0003 mm
3
virions×day
k1,r Rate CD4 T cells becomes infected by Vr 0.00005 mm
3
virions×day
kM1,s Rate macrophages becomes infected by Vs 0.00467
mm3
virions×day
kM1,r Rate macrophages becomes infected by Vr 0.001
mm3
virions×day
k2 Rate latently infected cells convert to actively infected cells 0.003 1day
k3 Rate infected macrophages infects CD4+ T cells 10−6 mm
3
cells×day
µTh Death rate of uninfected CD4+ Th cells 0.02
1
day
µTs Death rate of uninfected CD4+ Ts cells 0.02
1
day
µTr Death rate of uninfected CD4+ Tr cells 0.02
1
day
µTg Death rate of uninfected CD4+ Tg cells 0.02
1
day
µMh Death rate of uninfected Mh cells 0.005
1
day
µIp Death rate of uninfected Ip cells 0.001 1day
µIe Death rate of uninfected Ie cells 0.1 1day
µT li,s Death rate of latently infected T
l
i,s cells 0.1
1
day
µTai,s Death rate of actively infected T
a
i,s cells 0.24
1
day
µT li,r Death rate of latently infected T
l
i,r cells 0.2
1
day
µTai,r Death rate of actively infected T
a
i,r cells 0.5
1
day
µMah,s Death rate of actively infected M
a
h,s cells 0.04
1
day
µMah,r Death rate of actively infected M
a
h,r cells 0.07
1
day
µVs Death rate of sensitive viruses Vs 2.4
1
day
µVr Death rate of resistant viruses Vr 5
1
day
θi Scaling parameter for type i cells 1
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Table B3. Common parameters at both instances (Part 2)
Symbol Description Value
pis Growth rate of sensitive viruses (Vs) 8 1day
pir Growth rate of resistant viruses (Vr) 5 1day
p′s Specific immune response rate against Vs 0.020
cells
mm3×day
p′r Specific immune response rate against Vr 0.001
cells
mm3×day
q Growth rate of Ie due to infected cells and Ip 0.5 1day
QTh,Vs Percentage of Th cells that recognize the virus Vs 0
QTh,Vr Percentage of Th cells that recognize the virus Vr 0
QTs,Vs Percentage of Ts cells that recognize the virus Vs 0.90
QTs,Vr Percentage of Ts cells that recognize the virus Vr 0
QTr,Vs Percentage of Tr cells that recognize the virus Vs 0
QTr,Vr Percentage of Tr cells that recognize the virus Vr 0.90
QTg,Vs Percentage of Tg cells that recognize the virus Vs 0
QTg,Vr Percentage of Tg cells that recognize the virus Vr 0
r rate of growth for CD4+ T Helper cell population 0.03 1day
ρs Average number of virions Vs infecting a cell 1 virionscell
ρr Average number of virions Vr infecting a cell 1 virionscell
s1,Th Source/production Th cells 1
cells
mm3×day
s1,Mh Source/production of macrophages 1
cells
mm3×day
s′s Unspecific immune response rate against Vs 9.7
cells
mm3×day
s′r Unspecific immune response rate against Vr 0.0009
cells
mm3×day
Tmax Maximum CD4+ T Helper cell population level 1700 cellsmm3
Table B4. Common boundary conditions at both instances
Symbol Description Value
(
cells
mm3
)
Ie0 Initial value of I
e cells 10
Ip0 Initial value of I
p cells 10
M0h Initial value of Mh cells 1
T 0h Initial value of Th cells 900
T 0s Initial value of Ts cells 100
T 0r Initial value of Tr cells 100
T 0g Initial value of Tg cells 1
T l,0i,s Initial value of latently Ti cells infected by viruses Vs 10
T a,0i,s Initial value of actively Ti cells infected by viruses Vs 0
T l,0i,r Initial value of latently Ti cells infected by viruses Vs 10
T a,0i,r Initial value of actively Ti cells infected by viruses Vr 0
Ma,0h,s Initial value of actively Mh cells infected by viruses Vs 10
Ma,0h,r Initial value of actively Mh cells infected by viruses Vr 10
V 0s Initial value of viruses Vs 500
V 0r Initial value of viruses Vr 300
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